.33.34.35.36.37.38.39.40.41.Independent association of urinary F2-isoprostanes with survival in pulmonary arterial hypertension. Chest 2012, 142:86976. Crosswhite P, Sun Z: Nitric oxide, oxidative anxiety and inflammation in pulmonary arterial hypertension. J Hypertens 2010, 28:20112. Samuni Y, Goldstein S, Dean OM, Berk M: The chemistry and biological activities of N-acetylcysteine. Biochim Biophys Acta 1830, 2013:4117129. Cortijo J, Cerda-Nicolas M, Serrano A, Bioque G, Estrela JM, Santangelo F, Esteras A, Llombart-Bosch A, Morcillo EJ: Attenuation by oral N-acetylcysteine of bleomycin-induced lung injury in rats. Eur Respir J 2001, 17:1228235. Kharazmi A, Nielsen H, Schiotz PO: N-acetylcysteine inhibits human neutrophil and monocyte chemotaxis and oxidative metabolism. Int J Immunopharmacol 1988, 10:396. Haleagrahara N, Julian V, Chakravarthi S: N-acetylcysteine gives cardioprotection by decreasing cardiac lipid hydroperoxides and 8-isoprostane level in isoproterenol-induced cardiotoxicity in rats. Cardiovasc Toxicol 2011, 11:37381. Foltz WU, Wagner M, Rudakova E, Volk T: N-acetylcysteine prevents electrical remodeling and attenuates cellular hypertrophy in epicardial myocytes of rats with ascending aortic stenosis. Fundamental Res Cardiol 2012, 107:290. Handoko ML, Schalij I, Kramer K, Sebkhi A, Postmus PE, van der Laarse WJ, Paulus WJ, Vonk-Noordegraaf A: A refined radio-telemetry strategy to monitor suitable ventricle or pulmonary artery pressures in rats: a valuable tool in pulmonary hypertension study. Pflugers Arch 2008, 455:95159. Price LC, Montani D, Tcherakian C, Dorfmuller P, Souza R, Gambaryan N, Chaumais MC, Shao DM, Simonneau G, Howard LS, Adcock IM, Wort SJ, Humbert M, Perros F: Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats.Tenatoprazole Proton Pump Eur Respir J 2011, 37:81322.STING-IN-7 Technical Information Gomez-Arroyo JG, Farkas L, Alhussaini AA, Farkas D, Kraskauskas D, Voelkel NF, Bogaard HJ: The monocrotaline model of pulmonary hypertension in perspective. Am J Physiol Lung Cell Mol Physiol 2012, 302:L363 369. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, Krishna Kumar R, Landzberg M, Machado RF, Olschewski H, Robbins IM, Souza R: Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013, 62:D34 41. Kabe Y, Ando K, Hirao S, Yoshida M, Handa H: Redox regulation of NF-kappaB activation: distinct redox regulation in between the cytoplasm plus the nucleus. Antioxid Redox Signal 2005, 7:39503. Value LC, Caramori G, Perros F, Gambaryan N, Dorfmuller P, Montani D, Casolari P, Zhu J, Dimopoulos K, Shao D, Girerd B, Mumby S, Proudfoot A, Griffiths M, Papi A, Humbert M, Adcock IM, Wort SJ: Nuclear factor-kB is activated inside the pulmonary vessels of sufferers with end-stage idiopathic pulmonary arterial hypertension.PMID:23329650 PLoS One particular 2013. in press. Sawada H, Mitani Y, Maruyama J, Jiang BH, Ikeyama Y, Dida FA, Yamamoto H, Imanaka-Yoshida K, Shimpo H, Mizoguchi A, Maruyama K, Komada Y: A nuclear factor-kappaB inhibitor pyrrolidine dithiocarbamate ameliorates pulmonary hypertension in rats. Chest 2007, 132:1265274. Kimura S, Egashira K, Chen L, Nakano K, Iwata E, Miyagawa M, Tsujimoto H, Hara K, Morishita R, Sueishi K, Tominaga R, Sunagawa K: Nanoparticle-mediated delivery of nuclear element kappaB decoy into lungs ameliorates monocrotaline-induced pulmonary arterial hypertension. Hypertension 2009, 53:87783. de Man FS, Tu L, Handoko ML, Rain S, Ruiter G, Francois C, Schalij I, Dorfmuller P, Simon.